Investors may believe the company's poor revenue performance won't improve, causing a low P/S ratio. The company's future revenue growth is expected to be weaker than the industry average, causing discomfort among shareholders.
Investors remain skeptical of Nurix Therapeutics' future despite strong performance, with its forecasted growth rate much lower than the industry's 235%. Current P/S ratio hints that expected growth may not justify a higher P/S, needing a turnaround to satisfy investor sentiment.
$ニューリックス セラピューティクス(NRIX.US)$Nurix Therapeutics (NASDAQ:NRIX) said that the FDA has placed a partial clinical hold on a Phase 1 study of its drug NX-2127 in the treatment of B-cell malignancies as the company’s shifts to a different manufacturing process for the product. Nurix said patients currently enrolled in the trial who are deriving clinical benefit are allowed to continue receiving the current drug product. The screening and enrollment of new patients has been paused. The company sai...
$ニューリックス セラピューティクス(NRIX.US)$Looking interesting here. just off ATL, recent good news. PT just set to 31! will be looking for place to take position for a swing. just thinking outloud
$ニューリックス セラピューティクス(NRIX.US)$Nurix Therapeutics Announces Collaboration With Seagen To Develop A Portfolio Of Degrader-Antibody Conjugates; Co. To Receive $60M Upfront Payment And Potential For $3.4B In Milestones Plus Royalties
Modest daily stock gains cinched a strong six months on Wall Street, fueled by investors' optimism that inflation is easing while the economy continues to hum. Fresh spending data added momentum on Friday, showing milder core-price increases in May compared with a month earlier, while consumer outlays continued to rise. The data lifted major stock indexes on a day of calm trading, rounding out the$Nasdaq Composite Index(.IXIC.US)$'s best f...
ニューリックス セラピューティクスに関するコメント
$タイシャ ジーン セラピーズ(TSHA.US)$ 21% FY 2023 results
$TFFファーマシューティカルズ(TFFP.US)$ 14% Clinical programs update
$ジャガーアニマルヘルス(JAGX.US)$ 14% Crofelemer commercialization
$アセリリン(SLRN.US)$ 4% Ph1/2 positive data
$デルキャス・システムズ(DCTH.US)$ 3% Closes $7M private placement
$セラス ライフサイエンシズ グループ(SLS.US)$ 0% Closes $20M offering & private placement
$イミューニック(IMUX.US)$ 1% Patent notice of allowance
$ニューリックス セラピューティクス(NRIX.US)$ 0...
Nurix said patients currently enrolled in the trial who are deriving clinical benefit are allowed to continue receiving the current drug product. The screening and enrollment of new patients has been paused.
The company sai...
まだコメントはありません